The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
Commentary|Videos|March 21, 2014
Developing Next-Generation Anti-Androgen Therapies for CRPC
Author(s)Robert Dreicer, MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer
Advertisement
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer (CRPC).
Clinical Pearls:
- Developing next-generation androgen receptor (AR) therapies is challenging because many have similar activity to drugs that are already approved
- Orteronel, an androgen synthesis inhibitor, was unable to meet its primary endpoint of improvement in overall survival compared with placebo in a phase III trial
- In order to gain approval, new AR-targeted drugs must be dramatically better than the drugs that are already available
Advertisement
Related to this article
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5